Charles River Laboratories International Inc.

Charles River Laboratories International is a contract research organization. The company has a laboratory animal medicine and science to develop a portfolio of discovery and safety assessment services. The company's segments are: Research Models and Services, which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides DSA services, including in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development; and Manufacturing Support, which ensures the production and release of products manufactured by the company's clients.
  • TickerCRL
  • ISINUS1598641074
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Charles River Laboratories Int'l, Inc. - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Our outlook remains cautious and we continue to expect heightened volatility and a potential retest of the February 2018 lows over the next several weeks. Near-term we are monitoring for S&P 500 support near 2,600 (i.e., the October low) and resistance near 2,817 or the 100- and 50-day moving averages. In today's report we outline our current concerns along with developments that would cause us to become more constructive on the market. • Sector Relative Strength Rankings (RSRs) & Weighting Recommendations. We are upgrading Financials to market weight. A longstanding concern we have cited ...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Property & Casualty Insurance names are staging price and RS reversal and/or breakouts. • A number of industrial manufacturing names are stabilizing and staging possible price and RS reversals. • Railroads related names are breaking out. A few truckers are also making positive inflections. A number of transports are highlighted in today's vital signs.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Biotechs continue to be leadership. We have highlighted a number of names in today's Vital Signs. • Many retail related names have pulled back to logical support. See today's Vital Signs for many of these stocks. • A number of Auto Component Suppliers and Homebuilders appear to be stabilizing. We did not highlight them in this report, but will continue to watch for reversals

Charles River Laboratories International Inc: 1 director

A director at Charles River Laboratories International Inc sold 7,500 shares at 343.169USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listi...

MarketLine Department

Bioanalytical Systems, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Bioanalytical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Bioanalytical Systems, Inc. (BASi or 'the company') is a provider of contract research services and other related services for pharmaceutical development. The company also manufactures scientific instruments for life sciences research. It provides various services such as formula...

MarketLine Department

Laboratory Corporation of America Holdings - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Laboratory Corporation of America Holdings Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Laboratory Corporation of America Holdings since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an orga...

MarketLine Department

Wuxi Pharmatech (Cayman) Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Wuxi Pharmatech (Cayman) Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Wuxi Pharmatech (Cayman) Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its comp...

MarketLine Department

Catalent Inc - Strategy, SWOT and Corporate Finance Report

Summary Catalent Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Catalent Inc (Catalent) is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The company offers complex advanced formulation delivery technologies, and related integrated solutions. It provides comprehensive pre-formulation...

MarketLine Department

Catalent Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Catalent Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Catalent Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highligh...

Charles River Laboratories Int'l, Inc. - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's announces completion of a periodic review of ratings of Charles River Laboratories Int'l, Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Charles River Laboratories Int'l, Inc.. Global Credit Research- 05 Feb 2021. New York, February 05, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with the same analytical unit.

Charles River Laboratories Int'l, Inc.: Update following upgrade to Ba1 CFR

Our credit view of Charles River, reflecting its strong and consistent free cash flow, offset by aggressive M&A appetite.

Charles River Laboratories Int'l, Inc. - September 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's upgrades Charles River's CFR to Ba1; outlook stable

Rating Action: Moody's upgrades Charles River's CFR to Ba1; outlook stable. Global Credit Research- 20 Nov 2020. New York, November 20, 2020-- Moody's Investors Service upgraded the ratings of Charles River Laboratories International, Inc. including the Corporate Family Rating to Ba1 from Ba2 and the Probability of Default Rating to Ba1-PD from Ba2-PD.

An unfavourable environment weighs on CHAS.RVR.LABS.INTL.INCO., which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of CHAS.RVR.LABS.INTL.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date September 3, 2019, the closing price was USD 130.79 and its target price was estimated at USD 111.46.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch